2022-2023 Drug Updates in Hematologic Malignancies

At JADPRO Live 2023 in Orlando, Rebecca L. Rezac, PharmD, BCOP, summarized key information on US Food and Drug Administration approvals from late 2022 to late 2023. Dr. Rezac described indications, mechanisms of action, and monitoring and management of side effects of new therapies for hematologic m...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the advanced practitioner in oncology 2024-04, Vol.15 (3), p.177-181
Main Author: Rezac, Rebecca L
Format: Article
Language:English
Subjects:
Meeting Reports
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:At JADPRO Live 2023 in Orlando, Rebecca L. Rezac, PharmD, BCOP, summarized key information on US Food and Drug Administration approvals from late 2022 to late 2023. Dr. Rezac described indications, mechanisms of action, and monitoring and management of side effects of new therapies for hematologic malignancies.
ISSN:2150-0878
2150-0886
DOI:10.6004/jadpro.2024.15.3.4